Ph.D., CEO, Eutropics Pharmaceuticals
Biography
Michael Cardone leads Eutropics’ efforts to achieve corporate and scientific milestones. The company is using novel technology to extract unique insights from patient cancer cells that can be used to guide treatment. The PRIMAB® platform provides a breakthrough approach in cell signaling protein complex detection for guiding development and use of therapies for patients with cancer and immune disease. The novel predictive diagnostic tools have demonstrated utility for personalized medicine approaches. Michael Cardone’s experience includes 20 years of scientific and business management at early to mid-stage biotech companies. Prior to Eutropics, he was a scientific co-founder of publicly traded Merrimack Pharmaceuticals, a Cambridge, MA-based company. Prior to this, he worked at MIT developing tools for small molecule drug target identification and validation. He received a Ph.D. from UCSF and completed post-doctoral studies at the Burnham Institute in La Jolla, CA.
Talk
Prediction of Tumor Cell Response to Therapy
Eutropics' unique panel of antibodies, “PRIMABS®”, enable detection of tumor cell mitochondrial priming, a key determinant of cancer responsiveness to treatments. The presence (or absence) of the critical pro-survival : pro-apoptotic protein complexes, is used as a predictive biomarker for personalized medicine. Such reagents have hitherto not been available.
Session Abstract – PMWC 2022 Silicon Valley
Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.
Sessions:
- 4th Generation Sequencing Technologies & Genome Mapping Systems
- Barrett Bready, Nabsys
- Alka Chaubey, Bionano Genomics
- Eli Glezer, Singular Genomics - Long-Read Sequencing Technologies
- Steve Turner, PacBio - Single Cell Genomics
- Michael Schnall-Levin, 10x Genomics - Spatial Transcriptomics
- Jason T. Gammack, Resolve Biosciences - Pathogen Identification
Session Chair: Charles Chiu, UCSF
- Philip Stevens, Noscendo - Metagenomics and Microbial Profiling
- Amrie Grammer, Ampel BioSolutions - ML/AI for Diagnosis & Prognosis
- Todd Dickinson, Arc Bio - Modern Technologies for Pathogen Identification + AI
Session Chair: Sivan Bercovici, Karius Dx - Novel SBS Methodology
- Josh Lauer, Ultima Genomics - Proteogenomics
- Nigel Beard, Encodia - Advances Proteomics - Stratifying Cardiovascular Risk to Decrease Cost of Care
Session Chair: Roy Smythe, SomaLogic
- Adrian Lee, UPMC
- Jamie Bauersmith, UPMC - Leveraging Immune System Diagnostics to Improve Disease Outcomes
Session Chair: Kathy Kamath, Serimmune, Inc
- Noah Nasser, Serimmune, Inc
- Sasha Tabachnikova, Yale - Evolving Alzheimer’s Disease Therapeutics with Neuro Diagnostic Therapies (PANEL)
Session Chair: Kevin Hrusovsky, Quanterix
- Charlotte Teunissen, Amsterdam UMC
- Henrik Zetterberg, University of Gothenburg
- Nicholas Ashton, University of Gothenburg - PMWC Showcase (NCI)
- Michael Cardone, Eutropics Pharmaceuticals
- Robert Meltzer, Fluent BioSciences
- Cynthia Taylor Lawley, Olink Proteomics
- Niro Ramachandran, Akoya Biosciences
- Asim Siddiqui, Seer
